78357-63-8

Usage

Uses

Used in Pharmaceutical Research:
(3,5-dimethylphenoxy)acetyl chloride is used as an acetylating agent for the synthesis of pharmaceuticals. It aids in the development of new drugs by facilitating the acetylation of various organic compounds, which can enhance their properties or create new therapeutic agents.
Used in Agrochemical Synthesis:
In the agrochemical industry, (3,5-dimethylphenoxy)acetyl chloride is used as a key intermediate in the synthesis of various agrochemicals. Its acetylating properties allow for the creation of new compounds that can be used in pest control, crop protection, and other agricultural applications.
Used in Organic Synthesis:
(3,5-dimethylphenoxy)acetyl chloride is utilized as a reagent in organic synthesis for the production of a wide range of organic compounds. Its versatility in acetylation reactions makes it a valuable tool in the synthesis of various organic molecules for research and commercial purposes.

Upstream product

• 5406-14-4 2-(3,5-dimethylphenoxy)acetic acid 
• 79-11-8 chloroacetic acid 
• 108-68-9 3,5-Dimethylphenol 
• 24242-74-8 ethyl 2-(3,5-dimethylphenoxy)acetate 

Downstream Products

• 19443-51-7 2-(3,5-Dimethyl-phenoxy)-N-(octahydro-naphthalen-4a-yl)-acetamide 
• 83793-87-7 2-(3,5-Dimethylphenoxymethyl)-8-iodoanthranil 
• 83793-85-5 2-(3,5-Dimethylphenoxymethyl)anthranil 
• 398488-24-9 AN-329/42138480 
• 651728-53-9 N-(3,5-dimethylphenoxyacetyl)-L-glutamic acid 
• 651728-28-8 6-[2-(3,5-dimethylphenoxy)acetylamino]hexanoic acid 
• 83793-59-3 (S)-2-[2-(3,5-Dimethyl-phenoxymethyl)-4-oxo-4H-quinazolin-3-yl]-5-guanidino-pentanoic acid 
• 83793-61-7 (S)-4-Carbamoyl-2-[6,8-dibromo-2-(3,5-dimethyl-phenoxymethyl)-4-oxo-4H-quinazolin-3-yl]-butyric acid 
• 83793-63-9 (S)-4-Carbamoyl-2-[2-(3,5-dimethyl-phenoxymethyl)-8-iodo-4-oxo-4H-quinazolin-3-yl]-butyric acid 
• 83793-60-6 (S)-2-[2-(3,5-Dimethyl-phenoxymethyl)-4-oxo-4H-quinazolin-3-yl]-3-phenyl-propionic acid 
• 83793-64-0 (S)-2-[2-(3,5-Dimethyl-phenoxymethyl)-8-iodo-4-oxo-4H-quinazolin-3-yl]-3-methyl-butyric acid 
• 83793-65-1 (R)-2-[2-(3,5-Dimethyl-phenoxymethyl)-8-iodo-4-oxo-4H-quinazolin-3-yl]-propionic acid 
• 83793-62-8 (2S,3S)-2-[2-(3,5-Dimethyl-phenoxymethyl)-4-oxo-4H-quinazolin-3-yl]-3-methyl-pentanoic acid 

Relevant academic research and scientific papers

INHIBITORS TO TARGET HIV-1 NEF-CD80/CD86 INTERACTIONS FOR THERAPEUTIC INTERVENTION

The compounds of Formula I, II, and III along with their stereoisomers, pharmaceutically acceptable salts, polymorphs, solvates and hydrates thereof are described in the present disclosure. The said compounds restore immune activation in case of infections or a disease associated with an HIV infection in a subject in need thereof.

Structure-based design, synthesis and evaluation of 2,4-diaminopyrimidine derivatives as novel caspase-1 inhibitors

Interleukin-1β converting enzyme contributes in various inflammatory and autoimmune diseases by maturing pro-inflammatory cytokines IL-1β, IL-18 and IL-33. Therefore, inhibition caspase-1 may provide a potential therapeutic strategy for the treatment of chronic inflammatory diseases. Here we have reported structure-based design, synthesis and biological evaluation of 2,4-diaminopyrimidine derivatives (6a-6w) as potential caspase-1 inhibitors. Six compounds 6m, 6n, 6o, 6p, 6q and 6r showed significant enzymatic inhibition with IC5 0 ranging from 0.022 to 0.078 μM. These compounds also displayed excellent cellular potency at sub-micromolar concentration. Moreover, molecular docking studies provided the useful binding insights specific for caspase-1 inhibition. All these results indicated that compounds 6m, 6n and 6o could be potential leads for the development of newer caspase-1 inhibitors as anti-inflammatory agents.

Privileged 1,2,4-oxadiazoles in anticancer drug design: Novel 5-aryloxymethyl-1,2,4-oxadiazole leads for prostate cancer therapy

Based on the structure of the previously identified leads, new series of compounds containing 1,2,4-oxadiazole core was designed. A small, diverse library of 51 compounds including both 2-(acylamino)ethyl and 2-ureidoethyl side chains was synthesized using parallel chemistry and tested for antiproliferative activity against prostate cancer DU-145 cell line. Four hit compounds - all belonging to 2-ureidoethyl series - were identified and three compounds were confirmed as 10-20 μM inhibitors. The similarity in compounds' periphery and the data obtained previously suggest a similar mode of action for these compounds which was postulated as tubulin inhibition and was confirmed by in silico docking. These data provide further evidence for the privileged character of 1,2,4-oxadiazoles in antiproliferative compound design.

Photoassisted Synthesis of Complex Molecular Architectures: Dearomatization of Benzenoid Arenes with Aza-o-xylylenes via an Unprecedented [2+4] Reaction Topology

A new method was developed for the photoinduced dearomatization of arenes through an intramolecular cycloaddition with aza-o-xylylenes generated by excited-state intramolecular proton transfer (ESIPT) in the readily available photoprecursors. The [2+4] topology of this cycloaddition is unprecedented for photo-dearomatizations of benzenoid aromatic carbocycles. It provides rapid access to novel heterocycles, cyclohexadieno-oxazolidino-quinolinols, as valuable synthons for a broad range of post-photochemical transformations. I'm so excited: Photoinduced dearomatization of arenes was achieved through intramolecular cycloaddition with aza-o-xylylenes generated by excited-state intramolecular proton transfer in the readily available photoprecursors. The [2+4] topology of this cycloaddition is unprecedented for photo-dearomatizations of benzenoid aromatic carbocycles and produces the novel heterocycles cyclohexadieno-oxazolidino-quinolinols.

1-arylsulfonyl-2-(Pyridylmethylsulfinyl) benzimidazoles as new proton pump inhibitor prodrugs

New arylsulfonyl proton pump inhibitor (PPI) prodrug forms were synthesized. These prodrugs provided longer residence time of an effective PPI plasma concentration, resulting in better gastric acid inhibition.

PRODRUGS OF PROTON PUMP INHIBITORS

Prodrugs of proton pump inhibitors of Formulas 1 through 4, (I-IV), where the symbols are as defined in the specification, and the R group includes at least one acidic group or its pharmaceutically acceptable salt, have improved aqueous solubility and bioavailability.

Method for treating glaucoma IIB

Provided is a method of decreasing intraocular pressure or improving ocular accommodation in an animal, including a human, comprising administering an intraocular pressure decreasing amount or ocular accommodation improving amount of a compound of the formula I or IA, wherein J is oxygen, sulfur, or N—Rd.